Clinical utility of lanreotide Autogel^® in gastroenteropancreatic neuroendocrine tumors

References

• YaoJCHassanMPhanAOne hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United StatesJ Clin Oncol200826183063307218565894
   PubMed Web of Science ®Google Scholar
• SaltzLTrochanowskiBBuckleyMOctreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumorsCancer19937212442488389666
   PubMed Web of Science ®Google Scholar
• di BartolomeoMBajettaEBuzzoniRClinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology GroupCancer19967724024088625251
   PubMed Web of Science ®Google Scholar
• StrosbergJKvolsLAntiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumorsWorld J Gastroenterol201016242963297020572298
   PubMed Web of Science ®Google Scholar
• BrazeauPValeWBurgusRHypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormoneScience1973179406877794682131
   PubMed Web of Science ®Google Scholar
• BrazeauPGulleminREditorial: Somatostatin: newcomer from the hypothalamusN Engl J Med1974290179639644206096
   PubMed Web of Science ®Google Scholar
• de HerderWWHoflandLJvan der LelyAJLambertsSWSomatostatin receptors in gastroentero-pancreatic neuroendocrine tumoursEndocr Relat Cancer200310445145814713257
   PubMed Web of Science ®Google Scholar
• ReisineTBellGIMolecular biology of somatostatin receptorsEndocr Rev19951644274428521788
   PubMed Web of Science ®Google Scholar
• SusiniCBuscailLRationale for the use of somatostatin analogs as antitumor agentsAnn Oncol200617121733174216801334
   PubMed Web of Science ®Google Scholar
• Grozinsky-GlasbergSShimonIKorbonitsMGrossmanABSomatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanismsEndocr Relat Cancer200815370172018524947
   PubMed Web of Science ®Google Scholar
• LambertsSWvan der LelyAJde HerderWWHoflandLJOctreotideN Engl J Med199633442462548532003
   PubMed Web of Science ®Google Scholar
• PatelYCSomatostatin and its receptor familyFront Neuroendocrinol199920315719810433861
   PubMed Web of Science ®Google Scholar
• BousquetCPuenteEBuscailLVaysseNSusiniCAntiproliferative effect of somatostatin and analogsChemotherapy200147Suppl 2303911275700
   PubMedGoogle Scholar
• BauerWBrinerUDoepfnerWSMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sci19823111113311406128648
   PubMed Web of Science ®Google Scholar
• Ben-ShlomoAMelmedSSomatostatin agonists for treatment of acromegalyMol Cell Endocrinol20082861–219219818191325
   PubMed Web of Science ®Google Scholar
• MelmedSMedical progress: acromegalyN Engl J Med2006355242558257317167139
   PubMed Web of Science ®Google Scholar
• Somatuline® Autogel® lanreotide injection [product monograph]Ipsen Biopharm LimitedUK2015
   Google Scholar
• FleseriuMAdvances in the pharmacotherapy of patients with acromegalyDiscov Med2014179632933824979253
   PubMed Web of Science ®Google Scholar
• PatelYCMolecular pharmacology of somatostatin receptor subtypesJ Endocrinol Invest19972063483679294784
   PubMed Web of Science ®Google Scholar
• MaurerRReubiJCSomatostatin receptorsJAMA19852531827412859379
   PubMed Web of Science ®Google Scholar
• KranticSGoddardISaveanuANovel modalities of somatostatin actionsEur J Endocrinol2004151664365515588232
   PubMed Web of Science ®Google Scholar
• Guillermet-GuibertJLahlouHCordelierPBousquetCPyronnetSSusiniCPhysiology of somatostatin receptorsJ Endocrinol Invest20052811 Suppl International59
   PubMedGoogle Scholar
• SchallyAVOncological applications of somatostatin analoguesCancer Res19884824 Pt 1697769852903792
   PubMed Web of Science ®Google Scholar
• ErratumCancer Res19894961618
   Google Scholar
• LambertsSWKrenningEPReubiJCThe role of somatostatin and its analogs in the diagnosis and treatment of tumorsEndocr Rev19911244504821684746
   PubMed Web of Science ®Google Scholar
• CerviaDBagnoliPAn update on somatostatin receptor signaling in native systems and new insights on their pathophysiologyPharmacol Ther2007116232234117719647
   PubMed Web of Science ®Google Scholar
• PatelYCGreenwoodMTPanettaRDemchyshynLNiznikHSrikantCBThe somatostatin receptor familyLife Sci19955713124912657674817
   PubMed Web of Science ®Google Scholar
• KumarMLiuZRThapaLChangQWangDYQinRYAntiangiogenic effect of somatostatin receptor subtype 2 on pancreatic cancer cell line: inhibition of vascular endothelial growth factor and matrix metalloproteinase-2 expression in vitroWorld J Gastroenterol200410339339914760765
   PubMed Web of Science ®Google Scholar
• ReubiJCSomatostatin and other peptide receptors as tools for tumor diagnosis and treatmentNeuroendocrinology200480Suppl 1515615477718
   PubMedGoogle Scholar
• BrunsCLewisIBrinerUMeno-TetangGWeckbeckerGSOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profileEur J Endocrinol2002146570717611980628
   PubMed Web of Science ®Google Scholar
• LescheSLehmannDNagelFSchmidHASchulzSDifferential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitroJ Clin Endocrinol Metab200994265466119001514
   PubMed Web of Science ®Google Scholar
• ReubiJCWaserBConcomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targetingEur J Nucl Med Mol Imaging200330578179312707737
   PubMed Web of Science ®Google Scholar
• PapottiMBongiovanniMVolanteMExpression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysisVirchows Arch2002440546147512021920
   PubMed Web of Science ®Google Scholar
• LambertsSWvan der LelyAJHoflandLJNew somatostatin analogs: will they fulfil old promises?Eur J Endocrinol2002146570170511980627
   PubMed Web of Science ®Google Scholar
• BocciGCullerMDFioravantiAIn vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonistsEur J Clin Invest200737970070817696959
   PubMed Web of Science ®Google Scholar
• BosmanFTCarneiroFHrubanRHTheiseNDWHO Classification of Tumours of the Digestive System4th edLyonInternational Agency for Research on Cancer (IARC)2010
   Google Scholar
• CapelliPFassanMScarpaAPathology – grading and staging of GEP-NETsBest Pract Res Clin Gastroenterol201226670571723582914
   PubMed Web of Science ®Google Scholar
• WilliamsEDSandlerMThe classification of carcinoid tumorsLancet19631727523823914000847
   PubMedGoogle Scholar
• SolciaEKloeppelGSobinLHHistological Typing of Endocrine TumoursNew York, NYSpringer2000
   Google Scholar
• MassironiSSciolaVPeracchiMCiafardiniCSpampattiMPConteDNeuroendocrine tumors of the gastro-entero-pancreatic systemWorld J Gastroenterol200814355377538418803349
   PubMed Web of Science ®Google Scholar
• PeracchiMConteDGebbiaCPlasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1Eur J Endocrinol20031481394312534356
   PubMed Web of Science ®Google Scholar
• BaudinEGigliottiADucreuxMNeuron-specific enolase and chromogranin A as markers of neuroendocrine tumoursBr J Cancer1998788110211079792158
   PubMed Web of Science ®Google Scholar
• GrimaldiFFazioNAttanasioRItalian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasmsJ Endocrinol Invest201437987590925038902
   PubMed Web of Science ®Google Scholar
• BurkePGLiQCostinMLMcMullanSPilowskyPMGoodchildAKSomatostatin 2A receptor-expressing presympathetic neurons in the rostral ventrolateral medulla maintain blood pressureHypertension20085261127123319001189
   PubMed Web of Science ®Google Scholar
• BajettaEProcopioGCatenaLLanreotide autogel every 6 weeks compared with lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III studyCancer2006107102474248117054107
   PubMed Web of Science ®Google Scholar
• BianchiADe MarinisLFuscoAThe treatment of neuroendocrine tumors with long-acting somatostatin analogs: a single center experience with lanreotide autogelJ Endocrinol Invest201134969269722067307
   PubMed Web of Science ®Google Scholar
• Martín-RichardMMassutíBPinedaETTD (Tumores del Tracto Digestivo) Study GroupAntiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II studyBMC Cancer20131342724053191
   PubMed Web of Science ®Google Scholar
• CaplinMEPavelMĆwikłaJBCLARINET InvestigatorsLanreotide in metastatic enteropancreatic neuroendocrine tumorsN Engl J Med2014371322423325014687
   PubMed Web of Science ®Google Scholar
• Buil-BrunaNDehezMManonANguyenTXTrocónizIFEstablishing the quantitative relationship between lanreotide Autogel®, chromogranin A, and progression-free survival in patients with nonfunctioning gastroenteropancreatic neuroendocrine tumorsAAPS J201618370371226908127
   PubMed Web of Science ®Google Scholar
• CaplinMEPavelMĆwikłaJBCLARINET InvestigatorsAnti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension studyEndocr Relat Cancer201623319119926743120
   PubMed Web of Science ®Google Scholar
• PalazzoMLombard-BohasCCadiotGKi67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumorsEur J Gastroenterol Hepatol201325223223823108416
   PubMed Web of Science ®Google Scholar
• FaggianoACarratùACGuadagnoESomatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real lifeOncotarget2016755538554726701729
   PubMedGoogle Scholar
• ModlinIMKiddMLatichIZikusokaMNShapiroMDCurrent status of gastrointestinal carcinoidsGastroenterology200512861717175115887161
   PubMed Web of Science ®Google Scholar
• RuszniewskiPIsh-ShalomSWymengaMRapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotideNeuroendocrinology200480424425115627802
   PubMed Web of Science ®Google Scholar
• VinikAIWolinEMLiyanageNGomez-PanzaniEFisherGAELECT Study GroupEvaluation of Lanreotide Depot/Autogel efficacy and safety as a carcinoid syndrome treatment (ELECT): a randomized, double-bind, placebo-controlled trialEndocr Pract20162291068108027214300
   PubMed Web of Science ®Google Scholar
• RuszniewskiPValleJWLombard-BohasCSYMNET Study GroupPatient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: an international observational studyDig Liver Dis201648555255826917486
   PubMedGoogle Scholar
• RicciSAntonuzzoAGalliLLong-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumorsAm J Clin Oncol200023441241510955874
   PubMed Web of Science ®Google Scholar
• JohansonVWilsonBAbrahamssonARandomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel(®) given by either self/partner or a health care professionalPatient Prefer Adherence20126703101723118529
   PubMedGoogle Scholar
• KhanMSEl-KhoulyFDaviesPToumpanakisCCaplinMELong-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel)Aliment Pharmacol Ther201134223524221585408
   PubMed Web of Science ®Google Scholar
• OrlewskaEBednarczukTKaminskiGKos-KudlaBLanroNET Study GroupLanroNET, a non-interventional, prospective study to assess the resource utilization and cost of lanreotide autogel 120 mg in Polish patients with neuroendocrine tumors – results of interim analysisContemp Oncol (Pozn)201418644244725784845
   PubMedGoogle Scholar
• FotouhiOKjellinHLarssonCProteomics suggests a role for APC-survivin in response to somatostatin analog treatment of neuroendocrine tumorsJ Clin Endocrinol Metab Epub2016726
   PubMed Web of Science ®Google Scholar
• GobeauxFFayNTaraboutCStructural role of counterions adsorbed on self-assembled peptide nanotubesJ Am Chem Soc2012134172373322136398
   PubMed Web of Science ®Google Scholar
• ValéryCPougetEPanditAMolecular origin of the self-assembly of lanreotide into nanotubes: a mutational approachBiophys J20089451782179517993497
   PubMed Web of Science ®Google Scholar
• IjazMBonengelSZupančičODevelopment of oral self nano-emulsifying delivery system(s) of lanreotide with improved stability against presystemic thiol-disulfide exchange reactionsExpert Opin Drug Deliv201613792392927020604
   PubMed Web of Science ®Google Scholar
• LeiteDMBarbuEPilkingtonGJLalatsaAPeptide self-assemblies for drug deliveryCurr Top Med Chem201515222277228926043734
   PubMed Web of Science ®Google Scholar